Fabry : National Initiative of Screening (FIND)
Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke.
The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke.
This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||National, Multicenter, Prospective Study of Screening of Fabry Disease in a Population of Men Over 28 Days Old and Less Than 55 Years, Hospitalized for an Ischemic Stroke.|
- Fabry disease's screening (Positive microdosage confirmed by a macrodosage) [ Time Frame: Positive microdosage confirmed by a macrodosage ] [ Designated as safety issue: Yes ]
- Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease [ Time Frame: patients affected by Fabry disease ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2007|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2008 (Final data collection date for primary outcome measure)|
Procedure: Blood sample
Please refer to this study by its ClinicalTrials.gov identifier: NCT00484549
|Hôpital Gabriel Montpied|
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Pierre Clavelou, Pr||Unaffilliated|